India's Glenmark Pharma gains after starting phase three cancer drug trial

Glenmark Pharmaceuticals

05/09/2025 05:57

** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks

** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod

** Company says clinical trial applications are underway in Russia, Brazil, and Mexico

** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG

** Stock up 27.3% YTD

 (Reporting by Aleef Jahan in Bengaluru)

 ((aleefjahan.cs@thomsonreuters.com))